Period 1 (24 h), N = 20 | Period 2 (36 h), N = 20 | Period 3 + follow-up (up to 37 days), N = 20 | |
---|---|---|---|
Administration route | Oral | IV infusion | Oral |
Patients with ≥ 1 AE | 2 (10.0) | 10 (50.0) | 8 (40.0) |
Patients with ≥ 1 SAE | 0 | 0 | 2 (10.0) |
Patients with an AE leading to discontinuation | 0 | 0 | 0 |
Patients with ≥ 1 IV selexipag-related AE | N/A | 7 (35.0)a | 2 (10.0)b |
Patients with ≥ 1 prostacyclin-associated AE | 0 | 7 (35.0)a | 1 (5.0)c |
Patients with ≥ 1 AE related to infusion site reactions | N/A | 2 (10.0) | 0 |
Patients with prostacyclin-associated AE leading to discontinuation | 0 | 0 | 0 |
Deaths | 0 | 0 | 0 |